Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer Carbonate for Secondary Hyperparathyroidism in CKD
NCT01191762Phase 3Completed
- Start
- Apr 2010
- Primary completion
- Aug 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) comparing Sevelamer Carbonate with Placebo (2 arms). Primary endpoint: Fractional Change in Parathyroid Hormone Concentration at 4 weeks. Started Apr 2010; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01191762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191762.